QPPV.COM KNOWLEDGE ASSESSMENT

XEVMPD Lifecycle Maintenance: Managing Variations, Transfers, Renewals and Withdrawals

Test your understanding of the concepts covered by XEVMPD Lifecycle Maintenance: Managing Variations, Transfers and Withdrawals.

Question 1 of 10Pass mark: 80%

Question 1 of 10 How should a suspension generally be reflected in lifecycle governance?

Delete the product because it is temporarily unavailable. Ignore the suspension because it does not change the product's chemical composition. Assess and maintain the relevant regulatory status information using the applicable XEVMPD process. Create a completely unrelated product record.

Question 2 of 10 Which situation most clearly represents under-reporting of XEVMPD maintenance?

An impact assessment concludes that an approved administrative change does not affect Article 57 data and documents the rationale. A variation changes a structured product attribute, but no one assesses its XEVMPD impact because the initial record was already acceptable. A transfer is reviewed for identity continuity and organisation mapping. A withdrawal is represented through the applicable lifecycle-status mechanism.

Question 3 of 10 A change affects QPPV details, pharmacovigilance enquiry information or the PSMF location. What should the organisation do?

Update only the internal organisational chart. Treat the change as unrelated to XEVMPD because no product attribute changed. Assess the relevant Article 57 pharmacovigilance information and maintain it through the applicable process. Wait until the next product variation before reviewing the information.

Question 4 of 10 Why do marketing-authorisation transfers require particular care in XEVMPD?

They affect only the product's commercial name. They change the relationship between the medicinal product and the responsible organisation and can affect lifecycle continuity. They are handled exclusively through pharmacovigilance systems. They require every product to receive a new identity.

Question 5 of 10 Which evidence set would best support inspection readiness for a lifecycle-maintenance transaction?

Only a screenshot of the final XEVMPD record Only the approved regulatory decision The regulatory evidence, documented impact assessment, assigned task, submitted transaction, acknowledgement, review and reconciliation records A statement from the data-entry user that the update was completed

Question 6 of 10 Why should an SOP distinguish between centrally authorised and non-centrally authorised products when describing transfer workflows?

The same workflow is legally identical for every authorisation pathway. The relationship between XEVMPD, PMS, SIAMED and organisation mappings may differ by authorisation pathway. Non-centrally authorised products do not require Article 57 maintenance. Centrally authorised products cannot undergo transfers.

Question 7 of 10 Which statement best distinguishes a regulatory procedure from its XEVMPD data impact?

Completion of the procedure automatically determines the exact XEVMPD transaction in every case. The regulatory procedure establishes what was authorised, but a separate assessment is needed to determine how that change should be represented in XEVMPD. XEVMPD determines whether the regulatory procedure was legally valid. A regulatory procedure and an XEVMPD update are always the same activity.

Question 8 of 10 What is the best operational response to the regulatory deadline?

Schedule the XEVMPD task for the final day of the 30-day period. Translate the regulatory deadline into earlier internal milestones for assessment, preparation, review, submission and reconciliation. Wait until the next periodic data review to consolidate all changes. Start the process only after the product has been commercially updated.

Question 9 of 10 A transfer involving 40 products results in three apparently new records rather than continued lifecycle records. What is the most appropriate interpretation?

The three products should automatically be accepted as new products. The issue may indicate a portfolio-level or systemic problem involving mapping, identifiers, preparation or quality control. Only the three product names need to be corrected. The remaining 37 products are proven to be correct and require no review.

Question 10 of 10 What is the most effective way to address the question of which system is authoritative?

Declare XEVMPD the universal source for every data element. Allow each department to use whichever system it prefers. Define the authoritative source, downstream systems and reconciliation responsibility for each data element. Use the system that was updated most recently, regardless of source evidence.

QPPV.com

XEVMPD Lifecycle Maintenance: Managing Variations, Transfers, Renewals and Withdrawals

Cookie Settings